E-mail

E-mail a Wiley Online Library Link

Jorge A. Garcia, Thomas E. Hutson, Dale Shepard, Paul Elson and Robert Dreicer Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer Cancer 117

Version of Record online: 4 OCT 2010 | DOI: 10.1002/cncr.25457

In this study, the efficacy of combined gemcitabine plus docetaxel as treatment for patients with metastatic, castrate-resistant prostate cancer was similar to the efficacy of single-agent docetaxel. The combination was moderately toxic and primarily had an impact on bone marrow reserve.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH